Quadrant Healthcare (uk) Limited

Andaris Limited

Quadrant Healthcare, Ltd.

Nicholas David Osborne

Richard A Johnson

Andrew Derek Sutton

Roy Harris

Cheryl Vanessa Rogerson

Spray-drying microcapsules using an aqueous liquid containing a volatile liquid

Removal of lipid from lipid-bound protein such as human serum albumin to produce defatted protein enhances ability of the protein to bind therapeutic agents for use as a carrier for the therapeutic agent. The defatted protein may be reloaded with cationic and/or anionic lipids such as fatty acids, e.g. DC-Chol, to modify charge, hydrophilicity or hydrophobicity of the defatted protein to further enhance ability of the defatted protein to bind a therapeutic agent. A reloaded lipid itself may be a therapeutic agent. The defatted protein may be produced as microparticles by spray-drying. Defatting can be achieved by removing fatty acids with acidified activated charcoal, or by solvent extraction. A complex of DNA and a microparticle of defatted protein containing a cationic or anionic lipid molecule can be used for gene therapy. Defatted albumin may be reloaded with aminocaprylic acid to provide a microparticle for binding DNA for parenteral delivery. Microparticles of defatted protein having a modified predetermined fatty acid profile may be used as an enhanced ultrasound contrast agent.

Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy

Microcapsules having a wall thickness of no more than 500 nm, and a bulk density of no more than 0.2 g.cm , are suitable for therapeutic or diagnostic use. They are aerodynamically light, and can be used for delivery to the lung, or diagnosis by ultrasound.

Microparticles and their therapeutic or diagnostic use

Preparation of hollow microcapsules by spray-drying an aqueous solution

Growing community of inventors

Nottingham, United Kingdom

Nicholas David Osborne